Longitudinal analysis of ocular disease in children with Mucopolysaccharidosis I after hematopoietic cell transplantation.
Corneal clouding, causing visual impairment, is seen in nearly all patients with Mucopolysaccharidosis type 1 (MPS-1). Hematopoietic cell transplantation (HCT) is able to stabilize disease in many organs. Residual disease in several tissues however is increasingly recognized. Data on the effect of HCT on ocular disease in patients with MPS-1 are contradictory. With this study we aim to clarify the long-term effect of HCT on ocular disease in these patients. Best Corrected Visual Acuity (BCVA), refraction, intra-ocular pressure (IOP), slit-lamp biomicroscopic and fundoscopic examinations including corneal clouding were prospectively collected from MPS-1 patients treated with HCT between 2003 and 2018. The course of corneal clouding and BCVA after HCT were analyzed using a linear mixed model. Other parameters studied were clinical phenotype, age at time of transplantation and hematological enzyme activity after transplantation. Outcomes of additional ophthalmologic tests were described. Additionally, IDUA and AGAL enzyme activities and GAGs concentration in tear fluid were determined. 24 engrafted MPS-1 patients were included (92% with >95% chimerism and normal enzyme activity after HCT). Corneal clouding stabilized first years after HCT, but increased rapidly beyond three years (p<0.0001). BCVA and IOP also worsened over time (p=0.01 and p<0.0001, respectively). IDUA activity in tear fluid remained very low in patients (p<0.0001). After initial stabilization in the cornea, ongoing ocular disease and low IDUA activity in tear fluid is seen in MPS-1 patients despite treatment with HCT, unveiling a weak spot of current standard therapy. New therapies that overcome these shortcomings are necessary to improve the late outcomes of patients.